Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

63%

5 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 4

3(50.0%)

Phase 3

2(33.3%)

N/A

1(16.7%)

6Total

Phase 4(3)

Phase 3(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04245215Phase 3Completed

Loss of RESponse to Ustekinumab Treated by Dose Escalation

Role: lead

NCT05299931Phase 3Active Not Recruiting

An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients with Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study

Role: lead

NCT06113913Phase 4Recruiting

Subcutaneous Infliximab After A Previous Intravenous Dose Optimization

Role: lead

NCT02914717Completed

The Belgian SMART Study Evaluating the Use of Golimumab for Ulcerative Colitis

Role: collaborator

NCT02634060Not ApplicableCompleted

Home basEd faecaL calProtectin Measurements Predicting Adalimumab Induction Destiny

Role: collaborator

NCT05992142Phase 4Completed

ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA

Role: lead

NCT03142113Completed

Clinical Outcome After Escalation and De-escalation of Adalimumab in Real Life in Ulcerative Colitis

Role: collaborator

NCT00554710Phase 4Completed

Top Down Versus Step Up Strategies in Crohn's Disease

Role: lead

All 8 trials loaded